*Shigella* is an important cause of diarrhoea, particularly in children less than five years of age. *Shigella* spp. is highly contagious due to its low infective dose and high transmission rate in areas with overcrowding and poor sanitary conditions[@ref1]. Depending on the virulence potential of the strain and the nutritional status of the individual, shigellosis can progress to severe disease[@ref2]. The Global Enteric Multicenter Study, a case-control study of moderate-to-severe paediatric diarrhoeal disease, identified enterotoxigenic *Escherichia coli* and *Shigella* spp. as the most common bacterial pathogens in Sub-Saharan Africa and South Asia[@ref3].

Although *Shigella* infection is mostly self-limiting disease, antibiotics are recommended to reduce the clinical course of illness and to prevent transmission. However, antimicrobial resistance (AMR) is an emerging concern among *Shigella* spp. particularly in Asia and Africa[@ref4]. Over the past decades, *Shigella* species have become increasingly resistant to most widely used antimicrobials[@ref5]. Despite the alarming increase in the AMR in bacterial pathogens in India, publicly available information concerning the molecular identity of resistance traits is minimal[@ref6][@ref7]. According to the WHO report, AMR pattern for *Shigella* varies with geographic location and with time[@ref5]. The continuing changing patterns of prevalent species and resistance of *Shigella* isolates indicate the need for monitoring antimicrobial susceptibility profiles[@ref8]. The mobile genetic elements play a significant role in transferring resistance genes horizontally to non-resistant isolates. These elements are believed to be responsible for the acquisition and dissemination of AMR among clinically relevant organisms[@ref9].

The recent advancement in whole-genome sequencing technologies for routine microbiology is well documented[@ref10]. However, there is limited information on the surveillance of diarrhoeagenic pathogens and their AMR pattern in developing countries. The availability of whole-genome sequences of antimicrobial-resistant pathogens enhances our knowledge of the molecular identity of resistance traits and their mechanism of dissemination within the microbial population. This study was aimed to generate the base line data of resistance, virulence and plasmid profiles of *Shigella* species isolated from clinical specimens through whole-genome sequencing.

Material & Methods {#sec1-2}
==================

*Shigella* strains isolated from stool specimen from patients with diarrhoea or dysentery during the year 2011-2017 at Christian Medical College, Vellore, India were included in the study. Culture and biochemical identification of isolates was done using standard protocol[@ref11]. Serologic confirmation was done by slide agglutination test using polyvalent somatic (O) antigen grouping sera, followed by monovalent antisera (Denka, Seiken, Japan) for *Shigella*-specific serotype identification. Antimicrobial susceptibility testing of isolates against ampicillin (10 μg), trimethoprim/sulphamethoxazole (1.25/23.75 μg), nalidixic acid (30 μg), norfloxacin (10 μg), cefotaxime (30 μg), cefixime (5 μg) and azithromycin (15 μg) was performed using Kirby-Bauer disc diffusion method[@ref12]. The results were interpreted using breakpoints recommended by the Clinical and Laboratory Standards Institute guidelines 2017[@ref12]. Quality control strains used were *E. coli* ATCC 35218 and *E. coli* ATCC 25922 for the antibiotics tested.

*Whole-genome sequencing:* Genomic DNA was extracted using the QiaSymphony DNA extraction platform (Qiagen, Hilden, Germany). Genome sequencing was performed using Ion Torrent (PGM, Life Technologies, Carlsbad, CA, USA) with 400 bp read chemistry (Life Technologies) as previously described[@ref13].

*Assembly & annotation:* The raw data were assembled *de novo* using AssemblerSPAdes v.5.0.0.0 embedded in Torrent suite server v.5.0.4. The genome sequence was annotated using PATRIC, the bacterial bioinformatics database and analysis resource (*<http://www.patricbrc.org>*), and the NCBI Prokaryotic Genome Annotation Pipeline (PGAP) (*<http://www.ncbi.nlm.nih.gov/genomes/static/Pipeline.html>*)[@ref14].

*Downstream genome analysis:* The whole-genome data were analyzed using open access tools at Centre for Genomic Epidemiology web-based server. AMR and virulence genes were identified using ResFinder 2.1 (*<https://cge.cbs.dtu.dk//services/ResFinder/>*)[@ref16], respectively, with 90 per cent threshold for identity and with 60 per cent of minimum length coverage, where reads were mapped to a reference database of acquired genes. Furthermore, the transferable resistance genes and chromosomal mutation in the quinolone-resistant determining region were studied through PATRIC database. The presence of plasmids was analyzed using PlasmidFinder 1.3 (*<https://cge.cbs.dtu.dk//services/PlasmidFinder/>*) with 95 per cent threshold for identity[@ref17]. These whole-genome shotgun sequences were deposited in DDBJ/ENA/GenBank ([Table I](#T1){ref-type="table"} for accession numbers).

###### 

Characteristics of *Shigella* isolates analyzed in this study (n=60)

  Isolate ID   Organism                        Resistant pattern        Acquired resistance genes                                                                                           Chromosomal mutation   Plasmid (Inc type)   Accession no.                                                       
  ------------ ------------------------------- ------------------------ ------------------------------------------------------------------------------------------------------------------- ---------------------- -------------------- ------------------------ ------------ ----------------------------- --------------
  FC1882       *S*. *boydii*                   SXT-NAL                  *str*A, *str*B, *aad*A1, *sul*II, *dfr*A1                                                                           D87-Y                  \-                   \-                       \-           IncFII                        MDDI00000000
  FC1764       *S*. *boydii*                   AMP-SXT                  *str*A, *str*B, *bla*~TEM-1B~, *qnr*S1, *sul*II, *tet*A, *dfr*A14                                                   \-                     \-                   \-                       \-           IncFII, IncFIB                MDDH00000000
  FC1661       *S*. *boydii*                   SXT-NAL-FIX              *aad*A1, *sul*I, *tet*A, *dfr*A1, *dfr*A4, *bla*~EC~                                                                S83-L                  \-                   \-                       ^\*^E135-V   IncA/C2, IncFII               MDGW00000000
  FC2833       *S*. *boydii*                   ALL SUSCEPTIBLE          \-                                                                                                                  \-                     \-                   \-                       \-           IncFII                        MDJL00000000
  FC1567       *S*. *boydii*                   AMP-SXT-NAL              *dfr*A3, *bla*~EC~                                                                                                  \-                     \-                   \-                       \-           IncFII                        MIIV00000000
  FC2117       *S*. *boydii*                   AMP-SXT                  *str*A, *str*B, *bla*~TEM-1B~, *qnr*S1, *sul*II, *tet*A, *dfr*A14                                                   \-                     \-                   \-                       \-           IncFII, IncFIB                MINP00000000
  FC2125       *S*. *boydii*                   SXT-NAL-NX               *aad*A1, *dfr*A1, *bla*~EC~                                                                                         \-                     \-                   \-                       \-           IncFII                        MINQ00000000
  FC2175       *S*. *boydii*                   SXT                      *aad*A1, *dfr*A1                                                                                                    \-                     \-                   \-                       \-           IncFII                        MINR00000000
  FC2710       *S*. *boydii*                   AMP-SXT-NAL (MS)         *str*A. *str*B, *bla*~TEM-1B~, *qnr*S1, *sul*II, *dfr*A14                                                           \-                     \-                   \-                       \-           IncFII, IncFIB                MINU00000000
  FC1180       *S*. *flexneri*                 AMP-SXT-NAL-NX (MS)      *str*A, *str*B, *aad*A1, *bla*~OXA-1~, *sul*II, *tet*B, *dfr*A1                                                     S83-L                  \-                   S80-I                    \-           \-                            MDJJ00000000
  FC1139       *S*. *flexneri*                 AMP-SXT                  *dfr*A3, *bla*~EC~                                                                                                  \-                     \-                   \-                       \-           \-                            MECX00000000
  FC1172       *S*. *flexneri*                 AMP-SXT-NAL-NX (MS)      *str*A, *str*B, *bla*~OXA-1~, *sul*II, *tet*B, *dfr*A1                                                              S83-L                  \-                   S80-I                    \-           \-                            MDJI00000000
  FC1056       *S*. *dysenteriae* serotype 3   NAL-TAX                  *str*A, *str*B, *aad*A1, *sul*II, *tet*B, *dfr*A1, *bla*~EC~                                                        \-                     ^\*^Q776-L           ^\*^C435-G, ^\*^S694-P   \-           IncFII                        MECW00000000
  FC1708       *S*. *dysenteriae* serotype 3   SXT-NAL                  *aad*A1, *bla*~OXA-1~, *tet*B, *dfr*A1                                                                              \-                     ^\*^Q776-L           ^\*^C435-G, ^\*^S694-P   \-           IncFII                        MIIX00000000
  FC1737       *S*. *dysenteriae* serotype 3   NAL                      *tet*B, *dfr*A1                                                                                                     \-                     ^\*^Q776-L           ^\*^C435-G, ^\*^S694-P   \-           IncFII                        MIIY00000000
  FC2531       *S*. *dysenteriae* serotype 3   AMP-NAL-TAX              *aad*A1, *bla*~OXA-1~, *tet*B, *dfr*A1, *bla*~EC~                                                                   \-                     ^\*^Q776-L           ^\*^C435-G, ^\*^S694-P   \-           IncFII                        MINS00000000
  FC2541       *S*. *dysenteriae* serotype 3   AMP-NAL-TAX              *aad*A1, *bla*~OXA-1~, *tet*B, *dfr*A1, *bla*~EC~                                                                   \-                     ^\*^Q776-L           ^\*^C435-G, ^\*^S694-P   \-           IncFII                        MINT00000000
  FC2383       *S*. *boydii*                   AMP-SXT-NAL              *str*A, *str*B, *aad*A1, *bla*~TEM-1B~, *qnr*S1, *sul*II, *dfr*A1                                                   \-                     \-                   \-                       \-           IncN, IncFII                  MDJK00000000
  FC1544       *S*. *boydii*                   AMP-SXT-NAL              *str*A, *str*B, *bla*~TEM-1B~, *qnr*S1, *sul*II, *dfr*A14                                                           D87-Y                  \-                   \-                       \-           IncFII, IncFIB                MECT00000000
  FC3196       *S*. *boydii*                   AMP-SXT-NAL              *str*A, *str*B, *aad*A1, *bla*~OXA-1~, *sul*II, *tet*B, *dfr*A1                                                     S83-L                  \-                   \-                       \-           IncFII                        MINV00000000
  FC288        *S*. *sonnei*                   AMP-SXT-NAL-NX           *str*A, *str*B, *bla*~EC~, *sul*II, *dfr*A1                                                                         S83-L                  \-                   S80-I                    \-           Col (BS512)                   NGWI00000000
  FC1373       *S*. *sonnei*                   AMP-SXT-NAL-NX           *str*A, *str*B, *bla*~EC~, *sul*II, *dfr*A1                                                                         S83-L                  \-                   S80-I                    \-           Col 156                       NGWH00000000
  FC1417       *S*. *flexneri* 4               AMP-SXT-NAL-NX-TAX-FIX   *aad*A1, *bla*~OXA-1~, *bla*~CTX-M-15~, *qnr*S1, *cat*A1, *sul*II, *tet*B, *dfr*A1                                  S83-L                  \-                   S80-I                    \-           IncFII, Col (MP18)            NGWG00000000
  FC1846       *S*. *flexneri* 6               AMP-SXT-NAL-TAX-FIX      *bla*~EC~, *aad*A1, *tet*B, *dfr*A1                                                                                 D87-Y                  ^\*^Q776-L           ^\*^Q506-L               \-           IncFII                        NGWF00000000
  FC2615       *S. flexneri* 6                 AMP-SXT-NAL              *aad*A1, *bla*~EC~, *sul*II, *tet*B, *dfr*A1                                                                        D87-Y                  ^\*^Q776-L           ^\*^Q506-L               \-           IncFII                        NGWE00000000
  FC906        *S*. *flexneri* 2               AMP-SXT-NAL-NX-TAX-FIX   *str*A, *str*B, *bla*~EC~, *bla*~OXA-1~, *cat*A1, *sul*II, *tet*B, *dfr*A1                                          S83-L                  \-                   S80-I                    \-           IncFII                        NGWD00000000
  FC1182       *S*. *flexneri* 1               AMP-SXT-NAL              *str*A, *str*B, *aad*A1, *sul*II, *bla*~TEM-1B~, *tet*A, *dfr*A1                                                    \-                     \-                   \-                       \-           Col (BS512), IncFIB (K)       NGWC00000000
  FC1772       *S*. *sonnei*                   AMP-SXT-NAL-NX-TAX-FIX   *bla*~EC~, *sul*I, *dfr*A5                                                                                          S83-L                  \-                   S80-I                    \-           Col 156                       NGWB00000000
  FC1659       *S*. *sonnei*                   SXT-NAL                  *str*A, *str*B, *aad*A1, *bla*~OXA-1~, *cat*A1, *sul*II, *tet*B, *dfr*A1                                            S83-L                  \-                   S80-I, ^\*^S542-P        \-           IncFII, IncI2                 NGWA00000000
  FC470        *S*. *flexneri* 2               AMP-SXT-NAL-NX-TAX-FIX   *str*A, *str*B, *bla*~TEM-1B~, *bla*~DHA-1~, *qnr*B4, *qnr*S1, mphA, *sul*I, *sul*II, *tet*A, *dfr*A17              \-                     \-                   \-                       \-           IncFII, IncFIB (K)            NGVZ00000000
  FC1247       *S*. *flexneri* 2               AMP-SXT-NAL-NX-TAX-FIX   *str*A, *str*B, *aad*A1, *bla*~EC~, *bla*~TEM-1B~, *qnr*S1, *sul*II, *tet*A, *dfr*A1                                S83-L                  \-                   ^\*^Q506-L               \-           IncFII, IncFIB (K)            NGVY00000000
  FC1607       *S*. *flexneri* 4               AMP-SXT-NAL-NX-TAX-FIX   *aad*A1, *str*A, *str*B, *bla*~EC~, *bla*~CTX-M\ 15~, *qnr*S1, *cat*A1, *sul*II, *tet*B, *dfr*A1                    S83-L                  \-                   S80-I                    \-           IncFII, IncFIB (K)            NGVX00000000
  FC1481       *S*. *flexneri* 4               AMP-SXT-NAL-NX-TAX-FIX   *str*A. *str*B, *aad*A1, *bla*~TEM-1B~, *bla*~OXA-1~, *bla*~CTX-M-15~, *qnr*S1, *cat*A1, *sul*II, *tet*B, *dfr*A1   S83-L                  \-                   S80-I                    \-           IncFII, IncFIB (K)            NGVW00000000
  FC3278       *S*. *sonnei*                   AMP-SXT-NAL              *str*A, *str*B, *bla*TEM1B, *sul*II, *dfr*A5                                                                        S83-L                  \-                   S80-I                    \-           Col 156, IncB/O/K/Z           NMYB00000000
  FC1244       *S*. *sonnei*                   SXT-NAL                  *str*A, *str*B, *sul*II, *dfr*A1                                                                                    S83-L                  \-                   S80-I                    \-           Col 156                       NMYA00000000
  FC3433       *S*. *flexneri* 2               AMP-SXT-NAL-TAX          *aad*A1, *bla*~EC~, *bla*~OXA-1~, *cat*A1, *tet*B, *dfr*A1                                                          S83-L                  \-                   S80-I                    \-           IncFII                        NMXZ00000000
  FC653        *S*. *sonnei*                   AMP-SXT-NAL              *bla*~EC~, *str*A, *str*B, *sul*II, *dfr*A1                                                                         S83-L                  \-                   S80-I                    \-           Col 156                       NMXY00000000
  FC1170       *S*. *flexneri* 2               AMP-SXT-NAL              *bla*~OXA-1~, *cat*A1, *tet*B, *dfr*A1                                                                              S83-L                  \-                   S80-I                    \-           IncFII                        NMXX00000000
  FC1824       *S*. *flexneri* 2               AMP-SXT-NAL              *str*A, *str*B, *bla*~OXA-1~, *cat*A1, *sul*II, *tet*B, *dfr*A1                                                     S83-L                  \-                   S80-I                    \-           IncFII                        NMXW00000000
  FC601        *S*. *flexneri* 1               AMP-SXT-AZM              *str*A, *str*B, *aad*A1, *bla*~TEM1B~, *qnr*S1, *sul*II, *tet*A, *dfr*A1                                            \-                     \-                   \-                       \-           Col 156                       NMXV00000000
  FC3209       *S*. *sonnei*                   SXT-NAL-NX               *str*A, *str*B, *sul*II, *dfr*A1                                                                                    S83-L                  \-                   S80-I                    \-           Col 156                       NMXU00000000
  FC666        *S*. *boydii*                   SXT-NAL                  *aad*A1, *sul*II, *tet*B, *dfr*A1                                                                                   S83-L, D87-Y           \-                   ^\*^Q506-L               \-           IncFII                        NMXT00000000
  FC1747       *S*. *sonnei*                   SXT-NAL                  *str*B, *str*A, *sul*II, *dfr*A1                                                                                    S83-L                  \-                   S80-I                    \-           Col 156                       NMXS00000000
  FC15         *S*. *sonnei*                   AMP-SXT-NAL-NX-TAX-FIX   *str*B, *str*A, *bla*~CTX-M-15~, *bla*~EC~ *sul*II, *dfr*A1                                                         S83-L                  \-                   S80-I                    \-           Col (BS512), Col 156, Incl1   NMXR00000000
  FC401        *S*. *flexneri* 1               AMP-SXT-NAL-NX           *str*A, *str*B, *aad*A1, *bla*~TEM-1B~, *qnr*S1, *sul*II, *dfr*A1, *dfr*A14                                         \-                     \-                   \-                       \-           IncFII, IncFIB (K)            NMXQ00000000
  FC420        *S*. *flexneri* 2               AMP-SXT-NAL-NX           *str*A, *str*B, *bla*~OXA-1~, *sul*II, *tet*B, *dfr*A1, *cat*A1                                                     S83-L                  \-                   S80-I                    \-           IncFII                        NMXP00000000
  FC248        *S*. *flexneri*                 AMP-SXT-NAL-NX           *bla*~OXA-1~, *tet*B, *dfr*A1, *cat*A1                                                                              S83-L                  \-                   S80-I                    \-           IncFII                        NMXO00000000
  FC1642       *S*. *boydii*                   SXT-NAL                  *aad*A1, *tet*B, *dfr*A1, *sul*II                                                                                   S83-L, D87-Y           \-                   ^\*^Q506-L               \-           IncFII                        PDYE00000000
  FC1655       *S*. *boydii*                   AMP-SXT-TAX-FIX          *str*A, *str*B, *aad*A1, *bla*~EC~, *bla*~CTX-M-15~, *qnr*S1, *sul*II, *dfr*A1                                      \-                     \-                   \-                       \-           IncFII                        PDYD00000000
  FC1676       *S*. *boydii*                   AMP-SXT                  *str*A, *str*B, *bla*~TEM-1B~, *qnr*S1, *sul*II, *tet*A, *dfr*A14                                                   \-                     \-                   \-                       \-           IncFII, IncFIB (K)            PDYC00000000
  FC1706       *S*. *sonnei*                   SXT-NAL                  *dfr*A1                                                                                                             S83-L                  \-                   S80-I                    \-           Incl1, Col 156                PDYB00000000
  FC1628       *S*. *sonnei*                   SXT-NAL                  *str*A, *str*B, *sul*II, *dfr*A1                                                                                    S83-L                  \-                   S80-I                    \-           Col 156                       PDYA00000000
  FC1667       *S*. *sonnei*                   NAL                      *dfr*A1                                                                                                             S83-L                  \-                   S80-I                    \-           Col 156, ColpVC               PDXZ00000000
  FC1717       *S*. *boydii*                   AMP-SXT                  *str*A, *str*B, *bla*~TEM-1B~, *qnr*S1, *tet*A, *sul*II                                                             \-                     \-                   \-                       \-           IncFII, IncFIB (K)            PDXY00000000
  FC1653       *S*. *sonnei*                   SXT-NAL                  *str*A, *str*B, *sul*II, *dfr*A1                                                                                    S83-L                  \-                   S80-I                    \-           Col 156                       PDXX00000000
  FC1677       *S*. *sonnei*                   AMP-SXT-NAL-TAX-FIX      *str*A, *str*B, *bla*~EC~, *bla*~CTX-M-15~, *sul*II, *dfr*A1                                                        S83-L                  \-                   S80-I                    \-           Col 156, Incl1                PDXW00000000
  FC1405       *S*. *flexneri*                 AMP-SXT-TET-NAL-NX       *str*A, *str*B, *aad*A1, *bla*~OXA-1~, *cat*A1, *sul*II, *tet*B, *dfr*A1                                            S83-L                  \-                   S80-I, ^\*^R86-C         \-           IncFII                        PDXV00000000
  FC2101       *S*. *flexneri* 2               AMP-SXT-NAL-TAX-FIX      *aad*A1, *bla*~EC~, *bla*~CMY-4~, *dfr*A1                                                                           S83-L                  \-                   S80-I                    \-           IncB/O/K/Z                    PDXU00000000
  FC2414       *S*. *flexneri* 2               AMP-SXT-NX               *str*A, *str*B, *bla*~OXA-1~, *sul*II, *tet*B, *dfr*A1                                                              S83-L                  \-                   S80-I                    \-           IncFII                        PDXT00000000
  FC1954       *S*. *flexneri* 2               AMP-SXT-NAL-NX           *str*A, *str*B, *bla*~OXA-1~, *sul*II, *tet*B, *dfr*A1                                                              S83-L                  \-                   S80-I                    \-           IncFII                        PDXS00000000

^\*^Novel mutations. AMP, ampicillin; SXT, trimethoprim/sulphamethoxazole; NAL, nalidixic acid; NX, norfloxacin; TAX, cefotaxime; FIX, cefixime; AZM, azithromycin

Results {#sec1-3}
=======

Whole-genome sequences of 60 *Shigella* isolates were analyzed in this study, which included *S. dysenteriae* (n=5), *S. flexneri* (n=23), *S. boydii* (n=17) and *S. sonnei* (n=15). Among the study isolates, 68 per cent (n=41) were resistant to more than or equal to three antimicrobials, 30 per cent (n=18) were resistant to less than three antimicrobials and two per cent (n=1) were susceptible to all tested antimicrobials. Ampicillin susceptibility was lower in *S. flexneri* compared to *S. sonnei*, while the susceptibility profile of other antibiotics remained unchanged. The susceptibility profile of the isolates is shown in [Table I](#T1){ref-type="table"}.

*Whole genome sequencing:* The genome length for the *Shigella* isolates ranged from ca. 4.2 Mbp to ca. 4.6 Mbp with coverage of 36× to 100×. Genomes were screened for known acquired genes. The presence of resistance determinants conferring resistance to β-lactams, aminoglycosides, quinolones, cephalosporins, tetracycline and sulphonamides was identified, as detailed in [Table I](#T1){ref-type="table"}.

Species-wise antimicrobial resistance (AMR) gene analysis

*Shigella dysenteriae:* Of the five *S. dysenteriae* isolates, three were found to carry *bla*~OXA-1~ β-lactamase gene. All the isolates carried tetracycline (*tet*) and trimethoprim (*dfr*A1) resistance genes, whereas only one isolate carried sulphonamide gene (*sul*II). An aminoglycoside resistance gene such as *str*A/B and *aad*A1 was also identified. No mutations were observed in *gyr*A and *par*E genes, but novel mutations were observed in *gyr*B (Gln776 - Leu) and *par*C (Cys435 - Gly) genes. None of the isolates harboured cephalosporin resistance gene (Tables [I](#T1){ref-type="table"} & [II](#T2){ref-type="table"}).

###### 

Antimicrobial resistance genes distribution among *Shigella* serogroups % (n)

  *Shigella* serogroup     *bla*~OXA-1~   *bla*~TEM-1B~   *bla*~CTX-M-15~   *bla*~DHA-1~   *bla*~CMY-4~   *dfr*A1   *dfr*A14   *dfr*A17   *dfr*A4   *dfr*A5
  ------------------------ -------------- --------------- ----------------- -------------- -------------- --------- ---------- ---------- --------- ---------
  *S. dysenteriae* (n=5)   60 (3)         \-              \-                \-             \-             100 (5)   \-         \-         \-        \-
  *S. flexneri* (n=23)     56 (13)        22 (5)          13 (3)            4 (1)          4 (1)          91 (21)   4 (1)      4 (1)      \-        \-
  *S. boydii* (n=17)       6 (1)          41 (7)          6 (1)             \-             \-             53 (9)    29 (5)     \-         6 (1)     \-
  *S. sonnei* (n=15)       7 (1)          7 (1)           13 (2)            \-             \-             87 (13)   \-         \-         \-        13 (2)
                           *qnr*B4        *qnr*S1         *sul*I            *sul*II        *str*A         *str*B    *aad*A1    *tet*A     *tet*B    *cat*A1
                                                                                                                                                    
  *S. dysenteriae* (n=5)   \-             \-              \-                20 (1)         20 (1)         20 (1)    80 (4)     \-         100 (5)   \-
  *S. flexneri* (n=23)     4 (1)          30 (7)          4 (1)             74 (17)        65 (15)        65 (15)   52 (12)    17 (4)     69 (16)   43 (10)
  *S. boydii* (n=17)       \-             47 (8)          6 (1)             70 (12)        59 (10)        59 (10)   53 (9)     29 (5)     18 (3)    \-
  *S. sonnei* (n=15)       \-             \-              7 (1)             80 (12)        80 (12)        80 (12)   7 (1)      \-         7 (1)     7 (1)

[*Shigella flexneri:*]{.ul} All *S. flexneri* isolates were multi-drug resistant except one, which was resistant to ampicillin and trimethoprim/sulphamethoxazole alone. Among the β-lactamases, *bla*~OXA-1~, *bla*~TEM-1B~, *bla*~CTX-M-15~ genes were present in 13, 5 and 3 isolates, respectively. AmpC genes such as *bla*~DHA-1~ and *bla*~CMY-4~ were found each in single isolate. For plasmid-mediated quinolone resistance, *qnr*B4 (n=1) and *qnr*S1 (n=7) genes were identified. Fifteen isolates showed two identical mutations in the *gyr*A and *par*C genes. The mutations were observed at codon 83 in the *gyr*A gene and at codon 80 in the *par*C gene which resulted in the replacement of serine by leucine and isoleucine, respectively. Two isolates had an additional mutation at codon 87 in *gyr*A gene, resulting in the replacement of aspartic acid by tyrosine. Novel mutations were observed in *gyr*B (Gln776 to Leu) and *par*C (Gln506 to Leu and Arg86 to Cys) genes. No mutation was seen in the *par*E gene ([Table I](#T1){ref-type="table"}). Genes encoding trimethoprim (*dfr*A1, *dfr*A14, *dfr*A17) and sulphonamide (*sul*I and *sul*II) resistance were identified. Most of the isolates carried genes such as *str*A/B, *aad*A1, *tet*A/B and *cat*A1, conferring resistance to aminoglycosides, tetracycline and chloramphenicol ([Table II](#T2){ref-type="table"}).

[*Shigella boydii:*]{.ul} *S. boydii* isolates also carried the β-lactamase genes, *bla*~OXA-1~ (n=1), *bla*~TEM-1B~ (n=7), and *bla*~CTX-M-15~ (n=1). AmpC genes were not detected. Among the quinolone resistant isolates, only a *qnr*S1 gene was identified in eight isolates (Tables [I](#T1){ref-type="table"} & [II](#T2){ref-type="table"}). Four isolates showed mutations in *gyr*A (S83-L and D87-Y), two in *par*C (Q506-L) and a single isolate had a mutation in the *par*E (E135-V) gene. No mutation was seen in the *gyr*B gene. Resistance genes such as *dfr*A1, *dfr*A14, *dfr*A4, *sul*I, *sul*II, *str*A/B, *aad*A1 and *tet*A/B were identified in S. boydii isolates.

[*Shigella sonnei:*]{.ul} Like other serogroups, *S. sonnei* isolates were also found to carry *bla*~OXA-1~ (n=1), *bla*~TEM-1B~ (n=1), *bla*~CTX-M-15~ (n=2) genes. None of the isolates carried AmpC or the *qnr* genes. However, all *S. sonnei* isolates showed two identical mutations in *gyr*A and *par*C genes, S83-L and S80-I, respectively. One isolate had additional mutation in *par*C (S542-P) gene ([Table I](#T1){ref-type="table"}). The isolates also carried resistance genes for sulphonamides, aminoglycoside, tetracycline and chloramphenicol ([Table II](#T2){ref-type="table"}).

[*Virulence gene analysis:*]{.ul} The presence of virulence genes was analyzed using *E. coli* database. Most of the isolates were found to harbour virulence genes such as ipa involved in the entry of bacteria into epithelial cells. Other virulence genes such as *virF, senB, iha, capU, lpfA, sigA, pic, sepA, celb* and *gad* were also identified in the isolates. Distribution of these genes among *Shigella* serogroups are given in [Table III](#T3){ref-type="table"}.

###### 

Virulence genes observed among *Shigella* serogroups % (n)

  *Shigella* serogroup     *ipaH*   *ipaD*    *senB*     *virF*     *iha*      *capU*    *lpfA*     *sigA*     *pic*     *sepA*    *celb*   *gad*
  ------------------------ -------- --------- ---------- ---------- ---------- --------- ---------- ---------- --------- --------- -------- --------
  *S. dysenteriae* (n=5)   \-       100 (5)   100 (5)    100 (5)    100 (5)    100 (5)   100 (5)    100 (5)    \-        \-        \-       \-
  *S. flexneri* (n=23)     4 (1)    74 (17)   9 (2)      65 (15)    9 (2)      56 (13)   69 (16)    69 (16)    48 (11)   65 (15)   \-       \-
  *S. boydii* (n=17)       6 (1)    94 (16)   100 (17)   100 (17)   100 (17)   88 (15)   41 (7)     82 (14)    \-        \-        \-       6 (1)
  *S. sonnei* (n=15)       \-       7 (1)     93 (14)    7 (1)      \-         13 (2)    100 (15)   100 (15)   7 (1)     7 (1)     60 (9)   13 (2)

*Plasmid analysis:* Plasmid distribution among *Shigella* species is given in [Table IV](#T4){ref-type="table"}. IncFII type was the most prevalent plasmid among all four Shigella serogroups. *S. dysenteriae* isolates had only the IncFII type plasmid, whereas *S. flexneri* isolates were found to have IncFIB(K), IncFII, Col156, Col(BS512), ColMP18 and IncB/O/K/Z plasmids. *S. boydii* isolates were found to have plasmids such as IncFIB, IncA/C2 and IncN. Plasmids such as IncI2, IncI1 and ColpVC were identified in *S. sonnei*.

###### 

Plasmids prevalence among *Shigella* serogroups % (n)

  *Shigella* serogroup     IncFIB   IncFIB (K)   IncFII     IncA/C2   IncN    Col156    Col (BS512)   IncI2   Incl1    IncB/O/K/Z   ColpVC   Col MP18
  ------------------------ -------- ------------ ---------- --------- ------- --------- ------------- ------- -------- ------------ -------- ----------
  *S. dysenteriae* (n=5)   \-       \-           100 (5)    \-        \-      \-        \-            \-      \-       \-           \-       \-
  *S. flexneri* (n=23)     \-       26 (6)       74 (17)    \-        \-      4 (1)     4 (1)         \-      \-       4 (1)        \-       4 (1)
  *S. boydii* (n=17)       23 (4)   12 (2)       100 (17)   6 (1)     6 (1)   \-        \-            \-      \-       \-           \-       \-
  *S. sonnei* (n=15)       \-       \-           7 (1)      \-        \-      87 (13)   13 (2)        7 (1)   20 (3)   7 (1)        7 (1)    \-

Discussion {#sec1-4}
==========

*Shigella* remains a leading cause of childhood dysentery. The clones with high virulence and multidrug resistance (MDR) have spread globally where plasmids play a major role in conferring these characteristics[@ref18]. The pathogenesis of *Shigella* is related to various virulence factors located in the chromosome or large virulent *inv* plasmid carrying gene responsible for functions like host cell invasion and intracellular survival[@ref2][@ref19]. However, only a few studies have attempted to illustrate its molecular virulence profile. A recent study by Medeiros *et al*[@ref20] showed that the presence of virulence genes in *Shigella* was associated with various clinical symptoms such as intense abdominal pain and bloody stools. They also highlighted that the higher numbers of virulence genes were associated with resistance to more antimicrobials.

In this study, vast distribution of genes was observed among all four *Shigella* serogroups, especially in *S. flexneri. pic* and *sep*A genes were also seen more in *S. flexneri*. The shiga toxin gene (*stx*) is an important virulence determinant related to *S. dysenteriae*, but none of the *S. dysenteriae* isolates carried this gene.

The pathogens capacity to rapidly acquire AMR is a major concern. Development of AMR was common in all *Shigella* species, particularly in *S. sonnei* which were known to acquire resistance genes from *E. coli* through horizontal gene transfer mechanism[@ref21]. Furthermore, resistance in *S. flexneri* is well documented with several studies showing a high frequency of resistance to commonly used antimicrobials such as ampicillin and co-trimoxazole[@ref21].

In the present study, increased resistance was observed to first-line antibiotics such as ampicillin, trimethoprim-sulphamethoxazole and nalidixic acid. Therefore, these drugs should not be recommended for treatment unless susceptibility is known or expected based on local surveillance. In the present study, trimethoprim-sulphamethoxazole resistance was mainly due to *dhfr*1A gene followed by the *sul*II gene. The resistance to chloramphenicol, tetracycline and streptomycin was due to the presence of *cat*A1, tetA/B and of either *str*A/B or *aad*A1 genes or both.

Among β-lactams, ampicillin resistance was usually encoded by OXA-type β-lactamase genes followed by TEM. In the present study, the resistance was predominantly due to *bla*~OXA-1~ followed by *bla*~TEM-1~. The predominance of OXA-1 in *Shigella* has been reported earlier[@ref22]. Twenty one isolates in this study harboured *bla*~EC~ gene, a class C β-lactamase conferring resistance to β-lactam antibiotics. CTX-M-type β-lactamases *bla*~CTX-M-15~, was identified in all serogroups except *S. dysenteriae* and plasmid-mediated AmpC β-lactamases genes were found only in *S. flexneri* isolates. Increasing number of reports of third-generation cephalosporins resistance in Asia left limited options for effective therapy[@ref23].

The WHO has listed fluoroquinolone-resistant *Shigella* as one of its top concerns in the current international focus on AMR[@ref24]. In general, quinolone resistance involves the accumulation of mutations in DNA gyrase and DNA topoisomerase IV; and plasmid-mediated quinolone resistance (PMQR) determinants like *qnr*A, *qnr*B, *qnr*S and *aac(6)-Ib-cr* genes which confer low-level resistance to quinolones. In this study, the plasmid-mediated *qnr*S gene was widely distributed among *S. flexneri* and *S. boydii* isolates. *qnr*B4 gene was present only in *S. flexneri* isolates. Besides, mutation analysis of DNA gyrase and topoisomerase IV genes added more information in an understanding of resistance to fluoroquinolone in *Shigella*. Novel mutations were observed in *gyr*B, *par*C and *par*E genes. However, the detailed study on the impact of these mutations in conferring quinolone resistance needs to be done.

The presence of these AMR genes in most of the isolates was related with their phenotypic profile. However, phenotypic resistance in spite of the absence of genes represents that other mechanisms might be responsible for resistance, whereas the presence of resistance genes genotypically with no phenotypic expression corresponds to non-expression of AMR genes. One susceptible isolate did not carry any resistance genes but instead carried a plasmid. Another important factor involved in the spread of resistance was the presence of incompatible plasmid particularly, the IncF plasmid which was known to be associated with the worldwide emergence of clinically relevant extended-spectrum β-lactamases (ESBLs) and multiple AMR determinants[@ref25]. The present study showed the dominance of IncFII plasmid among the tested isolates. Beceiro *et al*[@ref18] have reported that IncF is a major incompatibility group involved in the co-transfer of resistance and virulence determinants. All the isolates harbouring virulence genes also harboured either single or more than one Inc type plasmid in this study, which further highlighted the significant association of these determinants in pathogenic bacteria.

The widespread emergence of MDR *Shigella* and increasing incidence with changing AMR patterns makes treatment a challenge for shigellosis. As shown here, AMR in *Shigella* spp. was serogroup-specific.

In conclusion, screening of AMR genes among *Shigella* genome showed that resistant gene distribution was variable among the *Shigella* serogroups. The findings of the present study also showed the species ability in acquiring AMR determinants and suggested the continuous surveillance of this species and its resistance profile particularly in *Shigella* endemic region.
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